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A B S T R A C T
Purpose
Colorectal cancer (CRC) treatment is largely determined by tumor stage. Despite improvements
made in the treatment of various types of metastatic disease, staging has not been reﬁned. The role
of tumor deposits (TDs) in staging remains debated. We have assessed the relation of TDs with
metastatic pattern to evaluate whether TDs might add signiﬁcant new information to staging.
Methods
We performed a systematic literature search that was focused on the role of TDs in CRC. Studies
with neoadjuvant-treated patients were excluded. Data on stage, histologic factors, and outcome
were extracted. Data from four large cohorts were analyzed for the relevance of the presence of
TDs, lymph node metastases (LNMs), and extramural vascular invasion (EMVI) on the pattern of
metastases and outcomes.
Results
Of 10,106 included patients with CRC, 22% presented with TDs. TDs are invariably associated with
poor outcome. Presence of TDs was associated with presence of LNMs and EMVI. In a pairwise
comparison, effects of TD were stronger than those of both LNMs and EMVI. In the logistic re-
gression model, TDs in combination with LNMs is the strongest predictor for liver (odds ratio [OR],
5.5), lung (OR, 4.3) and peritoneal metastases (OR, 7.0). Presence of EMVI adds information for liver
and lung metastases, but not for peritoneal metastases.
Conclusion
We have shown that TDs are not equal to LNMs or EMVI with respect to biology and outcome. We
lose valuable prognostic information by allocating TDs into nodal category N1c and only considering
TDs in the absence of LNMs. Therefore, we propose that the number of TDs should be added to the
number of LNMs to derive a ﬁnal N stage.
J Clin Oncol 35:1119-1127. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Staging of cancer is one of the cornerstones of
cancer treatment. The TNM staging system is an
anatomically based classiﬁcation that is applied
worldwide for many tumor types. Originally, this
systemwas used to determine prognostic outcomes
and to enable the international comparison of
different cohorts. With increasing treatment pos-
sibilities, tumor stage has become one of the main
selection criteria for (adjuvant) therapy. In co-
lorectal cancer (CRC), stage III patients are gen-
erally treated with systemic adjuvant therapy, as are
patients with high-risk stage II disease.1,2
However, for many patients with metastatic
disease, cytotoxic therapy is no longer their
only treatment option and more widespread
multimodality treatment with curative intent has
become possible. Patients with oligometastases in
liver or lung can undergo curative treatment in
ever increasing numbers,3,4 and patients with
peritoneal disease can undergo cytoreduction
with hyperthermic intraperitoneal chemotherapy
treatment.5 Clinical trials that will investigate
treatmentwith adjuvant hyperthermic intraperitoneal
chemotherapy in high-risk patients are currently
recruiting.6 Therefore, we need more detailed
staging systems that enable a better estimation
for recurrence risk at different sites to guide new
treatment choices.
In recent editions of the TNM staging
system, inclusion of tumor deposits (TDs)
within nodal staging has given rise to world-
wide discussions.7-12 Other important prognostic
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features, such as extramural vascular invasion (EMVI), are ac-
knowledged but not included in staging. One may wonder whether
we lose useful information by ignoring the former and placing TDs
with different etiologies into the nodal category, N1c, only in the
absence of lymph node metastases (LNMs). If TDs are equal to
LNMs, both in prognostic and biologic sense, this would simplify
the staging systems as they can be placed in the N category without
loss of information; however, if TDs add information to staging,
either alone or taking into account their etiology, we should apply
speciﬁc substaging.
We assessed the prognostic impact of TDs by performing
a systematic review of existing data, investigated the association of
TDs with other histologic prognostic factors, and determined
whether TD status inﬂuenced the metastatic pattern in CRC. On
the basis of the results, we propose revisions to be considered for
the modern anatomic staging of CRC.
METHODS
Strategy for Search of Articles and Selection Criteria
A comprehensive literature search for published studies was per-
formed by using Embase and Medline databases (OvidSP software; Ovid
Technologies, New York, NY) from inception to July 29, 2015 using the
following keywords: “tumor deposits” or “microfoci” or “non-nodal” or
“nodal independent” or “neoplastic foci” or “tumor aggregate” or “dis-
continuous” or “extranodal” or “staging” in combination with “Colorectal
Neoplasms”[Mesh] “Cecal Neoplasms”[Mesh] or “colorectal” or “colon”
or “rectum” or “rectal” and “cancer” or “carcinoma” or “tumor”, limited by
“Survival Analysis”[Mesh]. Additional searches were performed by manual
cross-referencing.
Only original studies that were published in English with at least 100
patients were selected. In case of overlapping patient data, results of the
largest study or of the study with longest follow-up were included in this
meta-analysis. Studies in which histology was not reviewed for whole
cohorts were excluded, as reporting on TDs without histologic review is
unreliable and incomplete. Studies that included patients who were treated
with neoadjuvant therapy were excluded. Test and validation cohorts that
have been described in the individual studies are separately analyzed.
Data Extraction
For each study, the number of patients in both the TD-positive and
TD-negative groups were obtained. Data on tumor stage, histologic factors,
5-year disease-free survival (DFS), 5-year disease-speciﬁc survival (DSS),
and 5-year overall survival (OS) were extracted from all studies. Data were
entered in SPSS for Windows version 22 (SPSS, Chicago, IL) and Review
Manager (version 5.3; Cochrane Tech, London, United Kingdom). Data
were retrieved by two independent investigators (I.D.N. and N.K.).
Quality Assessment and Risk of Bias
A scale to assess the quality of study reporting was developed on the
basis of the REMARK guidelines and focused on TDs (Appendix Table A1,
online only).13,14 All studies were subjected to quality assessment; studies
that were only used for correlation of TDs with other factors were subjected
to quality assessment in which outcome-speciﬁc items were left out. The
association between the quality of reporting and the hazard ratio (HR) was
analyzed with scatter plots and nonparametric correlation testing. Pub-
lication bias was assessed by symmetry in funnel plots.
Cohort Description
Data from four cohorts was further explored to determine the as-
sociation between TDs and metastatic patterns. These cohorts have been
extensively described elsewhere.9,15 In brief, the ﬁrst cohort is the test
cohort from the Japanese Society for Cancer of the Colon and Rectum,
which included 1,716 patients with stage I to III CRC who underwent
curative surgery between 1994 and 1998, with an average follow-up of
93 months.15 The validation cohort from the Japanese Society for Cancer
of the Colon and Rectum included 2,242 patients with stage I to III CRC
who underwent curative surgery between 1999 and 2003, with an average
follow-up of 68 months.15 The UK cohort consists of 455 patients with
stage I to IV CRC who were included in the Medical Research Council
CLASICC trial between July 1996 and July 2002, with an average follow-up
of 63 months.9 The Swedish cohort represents a consecutive case series
from Falu Lasarett of 505 patients with stage I to IV CRC who underwent
surgery between 1998 and 2000, with an average follow-up of 63 months.9
Histology from all cases was reviewed with special attention for TDs, as has
been described before.9,15
Statistical Analysis
A meta-analysis was performed with all available studies on corre-
lation in terms of risk ratios (RRs) with 95% CI. Data of univariable and
multivariable analyses were entered in terms of HR with 95% CI. If no HR
was reported, it was calculated from the published data,16 but only in
studies with data on minimum and maximum follow-up times. A random
effects model with inverse variance weighting of studies was used. In this
model, each study was given a weight that was equal to the inverse of the
variance of the effect estimate and served to minimize the variance of the
combined effect. Forest plots were used to demonstrate consistency of
results. For effect size, Z-statistic was used (standardized mean difference).
Heterogeneity was assessed by using a x2 test for heterogeneity with
a P value of , .10 to show the presence of signiﬁcant heterogeneity.
Furthermore, we applied I2 statistic—percentage of variation across studies
that is a result of heterogeneity rather than chance—in combination with
Articles (N = 1,179)
Excluded
Articles (n = 17)
Additional articles
 (n = 2)
Articles (n = 36)
Insufficient data
Overlapping cohorts 
< 100 patients
Neoadjuvant therapy
No histology review
Nonhuman
No original data
No data on TD
Not about CRC
Duplicates n = 283
n = 97
n = 6
n = 6
n = 7
n = 1
n = 2
n = 3
n = 11
n = 176
n = 572
Not published in English
Excluded
Fig 1. Flowchart of the article search strategy for systematic review. CRC,
colorectal cancer; TD, tumor deposit.
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Tau-squared—estimate of between-study variance in a random effect
meta-analysis. In case of heterogeneity, subanalyses for sample size,
timeframe, and TNM stage were performed to identify the potential source
of the heterogeneity. Logistic regression analysis was used to investigate the
multivariable relationship of pathologic factors that predicted liver, lung,
and peritoneal metastases in the four cohorts. In logistic regression an-
alyses, the reference group used was the negative/negative group, that is,
N0/TD negative. In the model, all ﬁrst-order interactions were included,
adjusting for cohort, LNMs, TDs, EMVI, and the combination of
LNM*TD, LNM*EMVI, and TD*EMVI. The model was simpliﬁed by
leaving out nonstatistical interactions with a P value of. .10. Results were
reported as odds ratios (ORs) with 95% CI. A P value# .05 was considered
statistically signiﬁcant. Hosmer and Lemeshow test for goodness of ﬁt was
used to evaluate logistic regression models. We applied the Holm method
for stepdown Bonferroni correction of multiple testing for each factor.
RESULTS
Search Results
A total of 574 studies were retrieved by the Medline database
search, and 605 we found by using Embase. Duplicates were ex-
cluded (n5 283). A further 862 studies were excluded because they
did not meet general inclusion criteria (Fig 1). We added two ad-
ditional papers that fulﬁlled eligibility criteria.17,18 The remaining
36 papers concerned TDs in CRC. We excluded six studies because
of insufﬁcient patient numbers,19-24 one gave insufﬁcient data for
analysis,25 two studies did not perform histologic revision of all
historic cases,18,26 and seven studies had overlapping data.12,27-32
Three studies included neoadjuvant-treated patients.33-35
The remaining 17 studies, which comprised 10,106 patients,
were included in the meta-analysis. The main characteristics of the
studies are listed in Table 1.
Quality of the Reporting of the Included Studies
Studies were subjected to quality assessment (Appendix
Table A1). Thirteen studies were used for meta-analysis with
outcome,15,17,36,37,41-45,47-49 of which nine studies could also be
used for correlation of TDs with other factors.15,17,41-44,47-49 Two
additional studies had no data on outcome and were only used for
correlation of TDs with other factors.9,46 Moreover, three studies
that were identiﬁed in our systematic review provided insufﬁcient
data for meta-analysis.38-40 Themean percentage of items that were
reported in studies with outcome data was 66.6% (range, 39% to
84%). The mean percentage of items reported in studies with data
for correlation was 71.6% (range, 50% to 82%).
Frequency and Impact of TDs
The average frequency of TDs for all studies was 22.0% (range,
4.9% to 41.8%).
Data on the impact of TDs on DFS in univariable analysis was
available from ﬁve studies, which included, in total, 1,246 patients.
In the presence of TDs, DFS was signiﬁcantly decreased (HR, 2.2;
95% CI, 1.6 to 3.0; Fig 2A). Considerable heterogeneity was ob-
served among studies (I2 5 78%). With respect to the quality
assessment of studies, the percentage of items reported ranged
from 50% to 84%, and this did not correlate with the magnitude of
Table 1. Overview of the Included Studies
Study Origin of Cohort Period Stage No. of Cases TD, % Location Meta-Analysis Correlation Meta-Analysis Outcome
Al Sahaf et al (2011)36 Ireland NM III 114 28.9 Colon — DFS UV
DSS UV + MV
Goldstein et al (2000)37 United States 1973-1984 III 400 17.8 Colon — DFS UV + MV
Harrison et al (1994)38 United States 1964-1983 I-III 348 27.3 Rectum — —
Harrison et al (1995)39 United States 1965-1985 I -III 344 25.5 Colon — —
Jin et al (2015)40 United States 2001-2010 I-IV 483 28.0 Colon — —
Lin et al (2015)41 People’s Republic
of China
2003-2013 IV 146 41.8 Colorectal LNM, EMVI DFS UV + MV
DSS UV + MV
Nagayoshi et al (2014)42 Japan 1999-2006 II and III 344 10.2 Colorectal LNM, N, EMVI DFS UV + MV
OS UV + MV
Nagtegaal et al (2011)9 United Kingdom,
Sweden
1996-2002 I-IV 960 34.7 Colorectal LNM, N, EMVI —
Puppa et al (2007)43 Italy 1988-1999 III and IV 228 4.9 Colorectal EMVI DFS UV
DSS UV
Shimada and Takii (2010)44 Japan 2000-2005 I-III 214 41.1 Rectum LNM, EMVI DFS MV
OS MV
Song et al (2012)45 China 1994-2007 III 513 29.4 Colorectal — DSS MV
Tateishi et al (2005)46 Japan 1985-1995 II and III 544 17.5 Colorectal LNM, EMVI —
Tsutsumi et al (2012)47 Japan 2005-2009 NM 263 14.4 Colorectal LNM OS UV + MV
Ueno and Mochizuki (1997)17 Japan (NDMCH) 1980-1992 I-III 369 35.2 Rectum LNM OS UV
Ueno et al (2011, 2012)*12,15 Japan (JSCCR) 1994-2003 I-III 3,958 15.4 Colorectal LNM, N DSS UV
Von Winterfeld et al (2014)48 Germany 2003-2007 I-IV 414 24.9 Colorectal LNM, N DFS MV
DSS MV
OS MV
Yabata et al (2014)49 Japan 2000-2008 I-III 464 13.1 Colorectal LNM, EMVI OS MV
All studies 10,106 22.0
Abbreviations: DFS, disease-free survival; DSS, disease-speciﬁc survival; EMVI, extramural vascular invasion; JSCCR, Japanese Society for Cancer of the Colon and
Rectum; LNM, lymph nodemetastases;MV,multivariable analysis; N, nodal stage; NDMCH, National DefenseMedical College Hospital; NM, notmentioned; OS, overall
survival; TD, tumor deposit; UV, univariable analysis.
*Data from this cohort have been described in two separate papers.
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Fig 2. The impact of tumor deposits (TDs) on outcome.
(A and B) Disease-free survival: univariable (A) and
multivariable (B). (C and D) Disease-speciﬁc survival:
univariable (C) and multivariable (D). (E and F) Overall
survival: univariable (E) and multivariable (F). HR, hazard
ratio; SE, standard error; TD2, TD negative; TD1, TD
positive.
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HR (Spearman r 5 0.56; P 5 .35). Multivariable DFS analysis was
available in ﬁve studies that comprised 1,536 patients and that
conﬁrmed decreased DFS in the presence of TDs (HR, 2.0; 95% CI,
1.4 to 2.8; Fig 2B). Substantial heterogeneity was observed among
studies (I2 5 66%). With respect to the quality assessment of the
studies, the percentage of items reported ranged from 65% to 84%,
and this did not correlate with the magnitude of HR (Spearman
r 5 0.82; P 5 .13).
The effect of TDs on DSS in univariable analysis was de-
termined in ﬁve cohorts that comprised 4,446 patients (Fig 2C) and
that conﬁrmed decreased DSS in the presence of TDs (HR, 3.3;
95% CI, 2.2 to 4.7). Considerable heterogeneity was observed
among studies (I2 5 83%). With respect to the quality assessment
of the studies, the percentage of items reported ranged from 50%
to 79%, and this did not correlate with the magnitude of HR
(Spearman r 5 20.16; P 5 .78). Multivariable DSS analysis was
available in four studies that comprised 1,185 patients and that
conﬁrmed decreased DSS in the presence of TDs (HR, 1.7; 95% CI,
1.4 to 2.1; Fig 2D). No heterogeneity was observed among studies
(I2 5 0%). The percentage of items reported ranged from 50% to
79%, and this quality indicator did not correlate with the mag-
nitude of HR (Spearman r 5 20.80; P 5 .33).
The impact of TDs on OS was available from three univariable
and ﬁve multivariable cohorts with 814 and 1,699 patients, re-
spectively (Figs 2E and 2F). OS was decreased in the presence of
TDs (univariable HR, 2.9; 95% CI, 2.2 to 3.8; and multivariable
HR, 2.2; 95% CI, 1.7 to 2.8). No heterogeneity was observed in
the univariable analysis (I2 5 0%), nor the multivariable analysis
(I2 5 0%). For univariable studies, the percentage of items re-
ported ranged from 56% to 84%, which did not correlate with the
magnitude of HR (Spearman r 5 20.50; P 5 1.00). For multi-
variable studies, the percentage ranged between 65% and 84%,
which did not correlate with the magnitude of HR (Spearman
r 5 0.60; P 5 .35).
None of the analyses showed evidence of publication bias
(Appendix Fig A1, online only). Observed heterogeneity in DFS
and DSS analyses could not be explained by differences in sample
size, timeframe, and TNM stage. Despite the observed heteroge-
neity, the direction of the effect in the forest plots is rather con-
sistent. HR as a result of TD is smaller in the multivariable models,
as would be expected because additional variance is accounted for;
however, inclusion of these additional covariates does not diminish
the signiﬁcance of the HR as a result of TD. Additional information
about the covariates that were included in the multivariable an-
alyses are listed in Appendix Table A2 (online only).
Subdivisions of TD: Does it Matter?
The size of TDs inﬂuences prognosis: larger TDs (. 12 mm in
diameter) have a signiﬁcantly poorer DSS compared with small TD
(# 3 mm; HR, 2.5 and 3.2, respectively).15 Between 3 mm and
12 mm, there was a nonsigniﬁcant increase in HR as a function of
TD size. In another study44 small TDs, deﬁned as, 2 mm, showed
a good DFS compared with that of larger TDs.
The contour of TDs can be described as smooth or irregular.
Two studies11,44 of 214 and 3,958 patients demonstrated a trend
toward poorer outcomes in the irregular groups; however, no direct
comparison was performed.
Increasing numbers of TDs are associated with poor out-
come. In the absence of LNMs, four or more TDs were associated
with a signiﬁcantly shorter survival in a small group of patients
(n 5 17; 16.5 months v 32.5 months; P 5 .025).40 Goldstein and
Turner41 showed that, regardless of nodal status, the 5-year
survival of patients with three or more TDs was signiﬁcantly
worse compared with patients with only one or two TDs (2% v
24%; P , .01).
Associations Between TD and Histologic Risk Factors
The relationship between nodal status and the presence of TD
was studied in 13 cohorts with a total of 7,583 patients (Appendix
Fig A2A, online only). TDs were present in 8.7% of patients
without LNMs compared with 41.6% of patients with LNMs.
There were six cohorts in which the number of involved lymph
nodes was studied (Appendix Fig A2B); there was a signiﬁcant
increase in TDs with increasing N stage in all studies (P 5 .002,
Friedman test). RR for TDs in the presence of LNMs was 4.2 (95%
CI, 3.2 to 5.6; Appendix Fig A2A).
The relationship between TD and EMVI (as determined by
examination of hematoxylin-eosin–stained slides) was studied in
nine cohorts with a total number of 2,805 patients (Appendix Fig
A2C). TDs were present in 20.9% of patients without EMVI
compared with 31.6% of patients with EMVI. RR for TDs in the
presence of EMVI was 2.6 (95% CI, 1.8 to 3.7; Appendix Fig
A2C).
Comparison of LNMs, TDs, and EMVI
Two studies investigated the prognostic power of TDs in
combination with LNMs.44,46 Whereas absence and presence of
both TDs and LNMs was associated with the best and worst
outcomes, respectively, both studies suggest that the presence of
only TDs is associated with a worse outcome than the presence of
only LNMs.
To establish the value of TDs, LNMs, and EMVI in modern
staging, we analyzed original data from four large cohorts of
studies9,15 that were selected in this systematic review in cor-
relation with metastatic patterns, including both synchronous
and metachronous metastases. Three different metastatic pat-
terns were distinguished: liver metastases, lung metastases, and
peritoneal metastases. In the four cohorts, which had a total
of 4,918 patients, there were 397 liver metastases, 268 lung
metastases, and 92 peritoneal metastases. The distribution of
metastases was different between the cohorts, with higher
percentages of liver and peritoneal metastases in the Sweden
cohort (Fig 3A).
For RR at different metastatic locations (Fig 3B), the effect of
LNMs was similar to that of TDs; however, the combination of
TDs and LNMs was associated with a signiﬁcantly higher risk
of liver metastases than LNMs alone. When TDs and EMVI were
compared (Fig 3C), it was clear that the presence of TDs sig-
niﬁcantly increased RR of liver metastases (RR, 3.6; 95% CI, 2.6 to
5.0 v RR, 1.7; 95% CI, 1.3 to 2.3). RR of TDs was not different
from the RR of TD and EMVI combined. For lung metastases,
the combination of TDs and EMVI signiﬁcantly increased
RR compared with EMVI alone. When the impact of EMVI in
combination with LNMs was compared, it was clear that addition
jco.org © 2016 by American Society of Clinical Oncology 1123
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of LNMs caused a higher RR for both lung and liver metastases
(Fig 3D).
We subsequently evaluated the different factors by using
a logistic regression model (Table 2). For liver metastases, TDs,
LNMs, and EMVI were signiﬁcant, with ORs of 3.6, 2.6, and 1.4,
respectively. For lung metastases, the effects of TDs, LNMs, and
EMVI were comparable (OR, 2.9, 2.5, and 2.0, respectively). For
the development of peritoneal metastases, only TDs and LNMs
contributed signiﬁcantly (OR, 6.4 and 3.2, respectively), but not
EMVI. Combination of TDs and LNMs did not increase the risk of
peritoneal metastases compared with TDs alone.
DISCUSSION
In the current systematic review, we identiﬁed 17 large-scale studies
that investigated the role of TDs in CRC. In a collection of 10,106
patients with CRC patients, the incidence of TDs was 22%, which
illustrates its potential value. The presence of TDs was invariably
associated with a poorer outcome as illustrated by decreased DFS
(HR, 1.7 to 2.0), DSS (HR, 1.7 to 3.9), andOS (HR, 2.2 to 2.9). Some
unexplained heterogeneity was present in DFS and DSS analyses;
however, OS analyses did not show heterogeneity.
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Fig 3. Metastatic patterns in relation to lymph node metastases (LNM), tumor deposit (TD), and extramural vascular invasion (EMVI) and combinations thereof. (A)
Percentage of patients with different metastatic locations in the different cohorts. (B) Inﬂuence of LNM and TD on metastatic patterns. (C) Inﬂuence of EMVI and TD on
metastatic patterns. (D) Inﬂuence of LNM and EMVI on metastatic patterns. According to the Japanese classiﬁcation, no distinction between intramural vascular invasion
and EMVI is made.50 EMVI2, no EMVI; EMVI1, EMVI present; JSCCR, Japanese Society for Cancer of the Colon and Rectum; N0, no LNM; N+, LNM positive; TD2, TD
negative; TD1, TD positive.
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Recent editions of TNM have acknowledged the importance
of TD by incorporating it in nodal staging. In the 5th edition of
TNM,51 the size of TD was considered important, but this was
replaced by contour in the 6th edition52 and by local interpretation
in the 7th edition.53 Despite the clinical impact of these deﬁnitions,
limited data are available to study both size and contour. Two
studies15,44 have conﬁrmed that size matters by demonstrating that
larger TDs are associated with worse prognosis. Data on the impact
of contour is less convincing.
The correlation between TDs and other types of regional
spread might be part of the explanation of the poor progno-
sis. TDs occur more frequently in cases with perineural
invasion21,41,43 and lymphatic invasion.17,42-44,46,49 We summa-
rized the most relevant correlations and demonstrated increased
TDs in patients with LNMs and EMVI; however, data from
multivariable studies still demonstrate an independent prognostic
effect of TDs.
It is important to realize that TDs are not LNMs: the origin of
TDs is diverse. By serial sectioning in a series of 30 irregular
TDs,37 almost 40% showed a combined perineural, perivascular,
and intravascular origin. A perineural origin was present in 77%
of cases and an intravascular origin in 83% of cases. A similar
setup with 69 TDs54 showed similar diversity. Presence of vessels
and nerves in the majority of TDs explains the worse prognosis
of patients with TDs compared with that of patients with
LNMs alone. Tumor access to more than one anatomic highway
to metastatic locations creates more extensive tumor spread;
therefore, we decided to evaluate the metastatic patterns that
occur in the presence of TDs. The early study of Goldstein and
Turner37 suggested a signiﬁcant impact of TDs in the develop-
ment of intra-abdominal metastases. In their cohort, only 12% of
patients without TDs developed peritoneal metastases compared
with 44% of patients with TDs. In the current study, we examined
original data from four different patient cohorts and the impact of
TDs on the pattern of metastases. Presence of TDs and LNMs
more than doubled the RR (5.3 v 2.5) for liver metastases
compared with LNM alone. Similar trends are observed for other
metastatic patterns. A ﬁrst explanation would be that TDs indeed
reﬂect EMVI and thus explain the high risk of liver metastases55;
however, when we compared TDs and EMVI, the difference was
even more pronounced. Whether there is an unequivocal alter-
native biologic explanation56 remains to be investigated. From
these results, it is clear that TDs do not equate to LNMs, nor
recognizable EMVI, both in a prognostic and in a biologic sense.
This study shows that by allocating all TDs into a nodal category,
pN1c, and subsequently ignoring them in the presence of LNMs,
valuable prognostic information is lost. The same argument can
be made for EMVI; we also lose potential information on the
likely sites for recurrence.
This study conﬁrms that sufﬁcient consistent evidence exists
to now justify TD assessment in the management of CRC.
However, there are a number of signiﬁcant issues. The lack of
deﬁnition in the current edition of TNM is not acceptable as it
leads to poor interobserver agreement.57 True effects of the total
number of TDs have not been determined, nor has this aspect
been considered against the number of LNMs present. We do not
know the optimal way to classify TDs after neoadjuvant treat-
ment. Size of TDs seems to matter and further characterization is
required. It is not clear how we should integrate these prognostic
markers into the debate over when to use adjuvant therapy.58
Despite all of these issues, TDs and their number should be fully
included in TNM staging. Inclusion of TDs only in the absence of
LNMs is not justiﬁed by the evidence. TDs and their actual
number should be considered equal to the number of LNMs in
making treatment decisions; therefore, the number of TDs should
be added to the number of LNMs in nodal staging to derive a ﬁnal
N stage.
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Table 2. Logistic Regression Model for the Various Metastatic Locations
Factor Liver Metastases Lung Metastases Peritoneal Metastases
N0/TD2 1.00 1.00 1.00
N0/TD+ 3.57 (2.38 to 5.35) 2.86 (1.71 to 4.78) 6.44 (3.04 to 13.65)
N+/TD2 2.60 (1.96 to 3.44)* 2.49 (1.81 to 3.44)† 3.21 (1.75 to 5.90)‡
N+/TD+ 5.54 (4.23 to 7.25)* 4.29 (3.11 to 5.93)† 6.97 (3.96 to 12.25)‡
EMVI 1.38 (1.08 to 1.77) 2.01 (1.48 to 2.72) 1.25 (0.76 to 2.05)
Hosmer and Lemeshow goodness of ﬁt P = .476 P = .688 P = .498
NOTE. Data are given as adjusted odds ratio (95% CI). Data are corrected for cohort and all other listed variables.
Abbreviations: EMVI, extramural vascular invasion; TD2, tumor deposit negative; TD+, tumor deposit positive.
*P , .001.
†P = .004.
‡P = .018.
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Fig A1. Funnel plots for the meta-analyses as shown in Fig 2.
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TD1, TD positive.
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Table A2. Covariates That Were Included in Multivariable Analyses for Disease-Free Survival, Disease-Speciﬁc Survival, and Overall Survival per Included Study
Study pT Lymph Node TD Tumor Characteristic Treatment Other
Disease-free survival
Shimada and Takii pT pN* TD* Grade, LVI, size
Nagayoshi et al pT pN* TD* Grade*, LVI, VI ChT*, margins
Lin et al pN TD* Gender, LM*, extrahepatic
metastases
Goldstein et al LNM* TD* Grade*, LVI, VI, location Age
Von Winterfeld et al TD Grade, location ChT Gender, age, TNM
Disease-speciﬁc survival
Al Sahaf et al pT LN ratio*, EC*, N+ TD* Grade, LVI ChT* Gender, age
Song et al pT* pN* TD* LVI*
Von Winterfeld et al TD* Grade, location ChT Gender, age, TNM
Lin et al pN* TD* VI*, PNI CEA, LM*
Overall survival
Shimada and Takii pT pN TD* Grade, LVI, size*
Yabata et al pT* LNM TD* LVI*, VI, circumferential
occupancy
Age*
Nagayoshi et al pT pN* TD* Grade, LVI, VI ChT*, margins*
Tsutsumi et al pT* pN TD* TNM
Von Winterfeld et al TD* Grade, location ChT Gender, age, TNM
Abbreviations: CEA, blood levels of carcinoembryonic antigen: ChT, adjuvant chemotherapy; EC, extracapsular growth of positive lymph nodes; LM, number of liver
metastases; LNM, lymph node metastases; LN, lymph node; LVI, lymphatic invasion; PNI, perineural growth: TD, tumor deposit; VI, vascular invasion.
*Statistically signiﬁcant (P , .05).
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